Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ERGOSTAT vs ERGOLOID MESYLATES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.
Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.
FDA-approved: Acute treatment of migraine headache with or without aura,Off-label: Cluster headache, vascular headache
Treatment of age-related cognitive decline,Dementia (unlabeled use)
0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.
Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.
Terminal half-life is 2–3 hours (intravenous) and 2–4 hours (oral). Short half-life necessitates frequent dosing; duration of action limited to 2–4 hours.
2-4 hours for parent drug; clinical significance: drug accumulation unlikely with normal dosing intervals.
Primarily hepatic via CYP3A4. Undergoes extensive first-pass metabolism.
Hepatic metabolism via CYP3A4 primarily; extensive first-pass effect.
Primarily hepatic (biliary-fecal) elimination: ~90% of a dose is excreted in feces as metabolites; renal excretion accounts for <5% unchanged drug.
Primarily fecal (biliary) as metabolites and unchanged drug; renal elimination accounts for less than 10% of the dose.
~65% bound to plasma albumin. Metabolites are less extensively bound.
Approximately 90% bound to albumin.
Approximately 0.2–0.3 L/kg, indicating primarily extracellular and peripheral tissue distribution with limited CNS penetration.
1.5-2 L/kg, indicating extensive tissue distribution.
Oral: ~10–20% (extensive first-pass metabolism); Sublingual: ~50–60% (avoids portal circulation); Rectal: ~30–40% (variable).
Oral: less than 10% due to extensive first-pass metabolism.
No specific adjustment; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation.
Not studied; no specific recommendations. Caution advised in severe renal impairment (GFR <30 m L/min).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Contraindicated in Child-Pugh class C (severe hepatic impairment). Use with caution in Child-Pugh class B; reduce dose by 50%.
Intravenous: 0.1 mg/m² body surface area every 2-4 hours, maximum 0.5 mg total; intramuscular: 0.2 mg every 2-4 hours, maximum 1 mg.
Not established; safety and efficacy not determined in pediatric patients.
Start at 0.1 mg intramuscularly or intravenously; monitor for hypertension with higher doses.
Initiate at 1 mg twice daily; titrate slowly. Monitor for orthostatic hypotension and cognitive effects.
Concomitant use with strong CYP3A4 inhibitors (e.g., protease inhibitors, macrolide antibiotics, azole antifungals) can lead to serious and/or life-threatening peripheral ischemia and vasospasm. Avoid coadministration.
No FDA black box warning.
Risk of ischemia (peripheral, cerebral, coronary) especially with prolonged use or overdose,Fibrotic complications (cardiac valvulopathy, pulmonary, retroperitoneal fibrosis) with chronic use,Medication overuse headache (MOH) with frequent use, Avoid in patients with uncontrolled hypertension, coronary artery disease, or peripheral vascular disease,Do not exceed recommended dosage; may cause ergotism
Use with caution in patients with hypotension, bradycardia, or history of psychosis; may cause orthostatic hypotension; monitor for signs of ergotism.
Concurrent use of potent CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, ketoconazole, ritonavir)
Hypersensitivity to ergot alkaloids; severe hypotension; acute or chronic psychosis; concurrent use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, azole antifungals).
Avoid grapefruit juice as it may increase ergonovine levels. No other significant food interactions.
Avoid grapefruit juice as it may increase drug levels. Limit caffeine intake as it may exacerbate vasoconstrictive effects. Maintain adequate hydration.
Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified as FDA Pregnancy Category X. Use in the first trimester may increase the risk of spontaneous abortion; in the second and third trimesters, it can precipitate preterm labor and fetal distress. There is no evidence of structural teratogenicity from direct drug effects, but the potential for ischemic injury to the fetus due to uterine hyperstimulation exists.
Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. Second/Third trimester: Contraindicated due to oxytocic effects causing uterine hypertonicity, placental hypoperfusion, and fetal distress. Use only if benefit outweighs risk for life-threatening conditions.
Ergonovine is excreted into breast milk. The M/P ratio is not well established, but small amounts are detectable. It may cause adverse effects in the nursing infant, including vomiting, diarrhea, and transient hypertension. Because of the risk of ergotism in the infant, breastfeeding is generally not recommended during therapy. A decision should be made to discontinue breastfeeding or discontinue the drug, considering the importance of the drug to the mother.
Excreted into breast milk; M/P ratio unknown. May suppress prolactin and reduce milk production. Potential for ergotism in neonates (vomiting, diarrhea, convulsions). Contraindicated during breastfeeding.
No dosing adjustments are recommended or studied because use in pregnancy is contraindicated. If exposure occurs accidentally or for life-threatening indications (e.g., severe postpartum hemorrhage), the same doses used in non-pregnant adults (0.2 mg IM or IV) may be employed, but with extreme caution due to heightened sensitivity to uterotonic effects. No pharmacokinetic studies in pregnancy exist; however, increased plasma volume and altered hepatic metabolism may require careful titration, but no specific evidence supports dose changes.
No established safe dose in pregnancy. Avoid use. If absolutely necessary, lowest effective dose and shortest duration, but no specific pharmacokinetic data available to guide adjustments.
ERGOSTAT (ergonovine) is an ergot alkaloid used for postpartum hemorrhage. It causes sustained uterine contraction. Contraindicated in hypertension, preeclampsia, and vascular disease. Administer IM or IV slowly over 1 minute to avoid severe vasoconstriction. Monitor blood pressure and uterine tone closely. Do not use in patients with hypersensitivity to ergot alkaloids.
Ergoloid mesylates are a mixture of dihydrogenated ergot alkaloids historically used for dementia, though efficacy is unproven. Avoid in patients with psychosis, severe bradycardia, or recent MI. Monitor for ergotism symptoms (vasospasm, ischemia). Not recommended due to lack of evidence.
This medication is given to control bleeding after childbirth.,It may cause nausea, vomiting, or dizziness.,Report severe headache, chest pain, or vision changes immediately.,Avoid smoking or using nicotine products while on this drug.,Do not breastfeed within 12 hours after the last dose; discuss with your doctor.
Take exactly as prescribed; do not double doses if missed.,Report signs of ergotism: cold/blue fingers/toes, muscle pain, tingling or numbness.,Avoid smoking and caffeine as they may worsen vasoconstriction.,May cause dizziness or fainting; avoid driving until you know how the drug affects you.,Do not use with other ergot alkaloids or triptans.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ERGOSTAT vs ERGOLOID MESYLATES, answered by our medical review team.
ERGOSTAT is a Ergot Alkaloid Antimigraine that works by Ergostat (ergotamine) is a serotonin (5-HT) receptor agonist, specifically at 5-HT1B and 5-HT1D receptors, leading to cranial vasoconstriction and inhibition of neurogenic inflammation. It also has partial agonist/antagonist activity at alpha-adrenergic receptors.. ERGOLOID MESYLATES is a Ergot Alkaloid that works by Ergoloid mesylates is a mixture of ergot alkaloids that acts as a partial agonist at dopamine D2 receptors and antagonist at alpha-adrenergic receptors, improving cerebral metabolism and blood flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ERGOSTAT and ERGOLOID MESYLATES depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ERGOSTAT is: 0.2 mg intramuscularly or intravenously every 2-4 hours for maximum 5 doses; not to exceed 1 mg total dose.. The standard adult dose of ERGOLOID MESYLATES is: Oral: 1 mg three times daily. Titrate to 2 mg three times daily after 2 weeks if tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ERGOSTAT and ERGOLOID MESYLATES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ERGOSTAT is classified as Category C. Ergostat (ergonovine) is contraindicated in pregnancy due to its potent uterotonic effects, which can cause uterine tetany, fetal hypoxia, and placental abruption. It is classified. ERGOLOID MESYLATES is classified as Category A/B. Ergoloid mesylates are ergot derivatives with uterotonic properties. First trimester: Avoid due to potential teratogenicity (limb defects, CNS malformations) based on animal data. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.